Clinical trials, peer-reviewed outcome data, comparative research, and the history of ibogaine science — from Howard Lotsof's first observations in 1962 to the ongoing Phase 2 trials. We cover the findings, including the ones that complicate the story.
Thirty combat veterans. A single ibogaine session. Eighty-three percent reporting significant improvement in PTSD symptoms at six-month follow-up. The most rigorous ibogaine study ever conducted on a veteran population — and a careful look at what those results do and don't tell us.
Read the analysis →The Stanford trial didn't just produce a data set. It preceded a presidential executive order directing $50M toward ibogaine research. How peer-reviewed outcomes translated into the first federal directive of its kind.
Read the analysis →83% improvement in a trial of 30 veterans is not the same as a promise. How to read ibogaine outcome data honestly when you're the one making a decision about your own care.
Read the guide →Before ibogaine was a compound in a clinical trial, iboga was a sacred plant in Gabon's Bwiti spiritual tradition. The ethnobotanical context that Western research still largely ignores.
Read the history →